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Background: Coronavirus membrane (M) proteins are capable of interacting with nucleocapsid (N) and envelope
(E) proteins. Severe acute respiratory syndrome coronavirus (SARS-CoV) M co-expression with either N or E is
sufficient for producing virus-like particles (VLPs), although at a lower level compared to M, N and E co-expression.
Whether E can release from cells or E/N interaction exists so as to contribute to enhanced VLP production is
unknown. It also remains to be determined whether E palmitoylation or disulfide bond formation plays a role in
SARS-CoV virus assembly.
Results: SARS-CoV N is released from cells through an association with E protein-containing vesicles. Further
analysis suggests that domains involved in E/N interaction are largely located in both carboxyl-terminal regions.
Changing all three E cysteine residues to alanines did not exert negative effects on E release, E association with N,
or E enhancement of VLP production, suggesting that E palmitoylation modification or disulfide bond formation is
not required for SARS-CoV virus assembly. We found that removal of the last E carboxyl-terminal residue markedly
affected E release, N association, and VLP incorporation, but did not significantly compromise the contribution of E
to efficient VLP production.
Conclusions: The independence of the SARS-CoV E enhancement effect on VLP production from its viral packaging
capacity suggests a distinct SARS-CoV E role in virus assembly.Background
Coronaviruses are enveloped viruses with 27–32 kb
single-strand positive-sense RNA genomes encoding
four structural proteins: nucleocapsid (N), spike (S),
membrane (M) and envelope (E) [1,2]. Translated on
free polysomes, highly basic N interacts with newly syn-
thesized viral genomic RNA to form helical nucleocap-
sids [3,4]. The M, S and E viral membrane proteins are
translated on membrane-bound polysomes, inserted into
the endoplasmic reticulum (ER), and transported to the
ER-Golgi intermediate compartment (ERGIC), where E
and M interact and trigger budding [5,6]. N and S are
incorporated into virions via interaction with M, with vi-
rions accumulating in large, smooth-walled vesicles that* Correspondence: chintien@ym.edu.tw
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virions from cells [2,7-11].
Coronavirus E is a small integral membrane protein
consisting of approximately 76 to 109 amino acids and
containing a hydrophobic domain. Several researchers
have suggested that coronavirus E functions as an ion
channel [12,13]. The role of the coronavirus E ion chan-
nel in the virus life cycle is not completely clear. The
addition of hexamethylene amiloride (HMA, an ion
channel inhibitor of mouse hepatitis coronavirus [MHV]
and human coronavirus 229E [HCoV229E] ion channel
activity in vitro) to culture medium blocks MHV and
HCoV229E replication [12], suggesting that the corona-
virus E ion channel plays a role in virus replication. Two
or three cysteine residues are located on the carboxyl
side of the hydrophobic domain in coronavirus E pro-
teins, with some serving as targets for palmitoylation
[14-17], which may contribute to virus assembly in the
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mation in the MHV [18], transmissible gastroenteritis
virus (TGEV) [19], bovine coronavirus (BCoV) [19], in-
fectious bronchitis virus (IBV) [5], and SARS-CoV [20].
Although M and N co-expression is also sufficient for
SARS-CoV VLP production [21,22], VLP yields are fur-
ther enhanced by E co-expression [23]. According to
these data, SARS-CoV E plays a supporting role in pro-
moting virus assembly and/or budding. E and N are
thought to be packaged into VLPs through separate and
individual associations with M; it remains unknown
whether E/N interaction exists, which might contribute
to enhanced virion production. MHV and IBV E proteins
are capable of release from cells as vesicles [5,24], imply-
ing a relationship between E release and its contribution
to virus production. Our goal for this study was to deter-
mine whether SARS-CoV N is capable of interacting
with E and cell release via an association with E-
containing vesicles. Our results indicate no correlation
between SARS-CoV E capacity to release or interact
with N, or its ability to promote VLP production.
Methods
Plasmid construction
Mammalian expression vectors encoding SARS-CoV M,
N, S and E were provided by G. J. Nabel [21]. A pair of up-
stream and downstream primers was used to amplify E-
coding fragments via PCR-based overlap extension muta-
genesis [25]. Primers used to introduce an HA or FLAG
epitope tag to the E amino or carboxyl terminus are
5′-TTCTGCGATATCGCCACCATGTACCCATACGAC
GTGCCTGACTACGCCTACAGCTTCGTGAGCG-3′
(containing a flanking EcoRV restriction site and HA tag-
coding nucleotides) and 5′-GCGGATCCTCACTTGTC
GTCGTCGTCCTTGTAGTCGCCCACCAGCAGGTCG
GGCAC-3′ (containing a flanking BamHI restriction
site and FLAG tag-coding nucleotides). The forward pri-
mer is 5′-GTCTGAGCAGTACTCGTTGCTG-3 (referred
to as the N primer) and reverse primer 5′-GGAAAGGA
CAGTGGGAGTGGCAC-3′ (referred to as the anti-N
primer). Primers used to construct designated E mutants
were EC3A, 5′- CTGAGGCTGGCCGCATATGCCGCG
AACATCGTGAACGTGAGC-3′ (reverse); 74LL/AA,5′-
GCAGATCTGGATCCTAGTTCACACGGCCGCGTCG
GGCACGCC-3′ (reverse); EΔ76V, 5′- CAGATCTGGA
TCCTAGTTCACAGCAGGTCGGGCAC-3′ (reverse).
The N primer serves as a forward primer while the anti-
N primer was used as a reverse primer for the second
round PCR amplification. Purified PCR product was
digested with BamHI and EcoRV and ligated into the
SARS-CoV E expression vector. When constructing N-
DsRed, the N primer served as the forward primer,
using the SARS-CoV N expression vector as a template
and 5′- GCGGATCCTGGGTGCTGTCGGCGCTG-3′as the reverse primer. Amplified PCR product was
digested with BamHI and SalI and ligated into pDsRed-
Monomer-N1 (Clontech). The cloned N-DsRed was
digested with NheI and BamHI and ligated into pEGFP-
N1 (Clonetech), yielding construct N-EGFP.
GST-M was constructed by digesting M expression
vector with EcoRV and NotI, ligated into pCDNA3.1-
myc-HisA (Invitrogen). The resultant construct was then
digested with BamHI and Not1, and then the M coding
sequence fragment was fused to carboxyl terminus of
GST, which is directed by a mammalian elongation fac-
tor Ia promoter [26]. GST-N fusions, as described previ-
ously [27], were constructed by fusing SARS-CoV N
coding sequences to the carboxyl terminus of GST.
Cell culture and transfection
293 T and HeLa cells were maintained in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with
10% fetal calf serum (GIBCO). Confluent cells were tryp-
sinized and split 1:10 onto 10 cm dishes 24 h prior to
transfection. For each construct, cells were transfected
with 20 μg of plasmid DNA using the calcium phosphate
precipitation method; 50 μm chloroquine was added to
enhance transfection efficiency. Unless otherwise indi-
cated, 10 μg of each plasmid was used for co-transfection.
Culture supernatant and cells were harvested for protein
analysis 2–3 d post-transfection. For HeLa transfection,
plasmid DNA was mixed with GenCarrier (Epoch Biolabs)
at a ratio of 1 μg to 1 μl; the transfection procedure was
performed according to the manufacturer’s protocols.
Western immunoblot
At 48–72 h post-transfection, supernatant from trans-
fected cells was collected, filtered, and centrifuged
through 2 ml of 20% sucrose in TSE (10 mM Tris–HCl
[pH 7.5], 100 mM NaCl, 1 mM EDTA plus 0.1 mM phe-
nylmethylsulfonyl fluoride [PMSF]) at 4°C for 40 min at
274,000 x g. Pellets were suspended in IPB (20 mM
Tris–HCl [pH 7.5], 150 mM NaCl, 1 mM EDTA, 0.1%
SDS, 0.5% sodium deoxycholate, 1% Triton X-100, 0.02%
sodium azide) plus 0.1 mM PMSF. Cells were rinsed
with ice-cold phosphate-buffered saline (PBS), collected
in IPB plus 0.1 mM PMSF, and microcentrifuged at 4°C
for 15 min at 13,700 x g to remove unbroken cells and
debris. Supernatant and cell samples were mixed with
equal volumes of 2X sample buffer (12.5 mM Tris–HCl
[pH 6.8], 2% SDS, 20% glycerol, 0.25% bromphenol
blue) and 5% β-mercaptoethanol and boiled for 5 min
or (for the M-containing samples) incubated at 45°C for
10 min. Samples were resolved by electrophoresis on
SDS-polyacrylamide gels and electroblotted onto nitro-
cellulose membranes. Membrane-bound M, M-FLAG,
HA-E, E-FLAG or GST proteins were immunodetected
using a SARS-CoV M rabbit anitserum, anti-HA (LTK
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monoclonal antibody at a dilution of 1:1,000. For
SARS-CoV N or S detection, a mouse monoclonal anti-
body [28,29] was used at a dilution of 1:5,000. The sec-
ondary antibody was a sheep anti-mouse or donkey
anti-rabbit horseradish peroxidase-(HRP) conjugated
antibody (Invitrogen), both at 1:5,000 dilutions.Laser scanning immunofluorescence microscopy
HeLa cells were split 1:80 onto coverslips 24 h before
transfection. Between 18 and 24 h post-transfection, , cells
were washed with PBS and permeabilized at room
temperature for 10 min in PBS plus 0.1% Triton X-100
following fixation at 4°C for 20 min with methanol/acet-
one (1:1). Samples were incubated with the primary anti-
body for 1 h and with the secondary antibody for 30 min.
Following each incubation, samples were subjected to
three washes (5 to 10 min each) with DMEM/calf serum.
Primary antibody concentrations were anti-HA at a dilu-
tion of 1:500. A rabbit anti-mouse rhodamine-conjugated
antibody at a 1:100 dilution served as the secondary anti-
body (Cappel, ICN Pharmaceuticals, Aurora, OH). After a
final DMEM/calf serum wash, the coverslips were washed
three times with PBS and mounted in 50% glycerol in PBS
for viewing. Images were analyzed and photographs taken
using the inverted laser Zeiss.Figure 1 SARS-CoV VLP assembly and release. 293 T cells were
co-transfected with SARS-CoV N, M and E expression vectors in
various combinations. M-FLAG or E-FLAG indicates a FLAG tagged at
the SARS-CoV M or E carboxyl terminus; HA-E denotes an HA tagged
at the SARS-CoV E amino terminus. DNA (5 μg) of each plasmid was
used for each transfection, with pBlueScript SK added to maintain aIodixanol density gradient fractionation
Supernatants from transfected 293 T cells were col-
lected, filtered, and centrifuged through 2 ml 20% su-
crose cushions as described above. Viral pellets were
suspended in PBS buffer and laid on top of a pre-made
10-40% iodixanol (OptiPrep) gradient consisting of
1.25 ml layers of 10, 20, 30 and 40% iodixanol solution
prepared according to the manufacturer’s instructions
(Axis-Shield, Norway). Gradients were centrifuged in a
SW50.1 rotor at 40,000 rpm for 16 h at 4°C; 500 μl frac-
tions were collected from top to bottom and densities
were measured for each. Proteins in each fraction were
precipitated with 10% trichloroacetic acid (TCA) and
subjected to Western immunoblotting.plasmid DNA level of 20 μg. At 48 h post-transfection, supernatants
and cells were collected and prepared for protein analysis as
described in Materials and Methods. Cell lysate samples (lanes 1 to
5) corresponding to 5% of total, and medium pellet samples
(lanes 6 to 10) corresponding to 50% of total, were fractionated by
10% SDS-PAGE and electroblotted onto nitrocellulose filters.
SARS-CoV M was probed with rabbit antiserum. SARS-CoV N and E
were detected with a mouse anti-N, anti-HA, or anti-FLAG
monoclonal antibody. N proteins from medium or cell samples were
quantified by scanning N band densities from immunoblots. Rations
of N level in media to those in cells were determined for each
samples and normalized to that of samples without HA-E or
E-FLAG co-expression.GST pull-down assay
GST pull-down protocols were as previously described
[27]. Briefly, 500 μl of PNS containing complete protease
inhibitor cocktail was mixed with 30 μl of glutathione
agarose beads (Sigma). All reactions took place at 4°C
overnight on a rocking mixer. Immunoprecipitate-
associated resin or bead-bound complexes were pelleted,
washed tree times with lysis buffer, two times with PBS,
eluted with 1X sample buffer, and subjected to SDS-10%
PAGE as described above.Results
SARS-CoV E is capable of associating with N
In a previous study we found that SARS-CoV M co-
expression with N leads to VLP formation, and that a
FLAG tagged at the SARS-CoV M carboxyl terminus
(M-FLAG) significantly inhibits N packaging into VLPs
[22]. Since N release into medium depends on an associ-
ation with M, and since E may promote VLP production,
we set out to confirm whether E complements M-FLAG
in N packaging into VLPs. Toward this goal we co-
expressed N with M-FLAG in the absence or presence
of SARS-CoV E tagged with either HA at the amino
terminus (HA-E) or with FLAG at the carboxyl terminus
(E-FLAG). As shown in Figure 1, N that was barely de-
tectable in medium became readily detected following
co-expression with HA-E (lanes 9 versus 10). Since N is
incapable of associating with M-FLAG, a simple explan-
ation would be the ability of E to promote N incorpor-
ation into VLPs via E/N interaction. E-FLAG was barely
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the FLAG tagged at the E carboxyl terminus affected E
release or E association with M and/or N. To confirm
that E-mediated N release is not due to HA tag, we co-
expressed N with E and found that E without HA tag
can still promote N release (data not shown), suggesting
that HA tag exerts no major impacts on E-mediated N
release.
Since SARS-CoV E and M are both capable of release
into medium, N detected in medium may be a result of
an association with released M-FLAG in the presence of
E, but not a result of direct E/N interaction. To rule out
this possibility and to confirm that a specific N-E inter-
action exists, we co-expressed N and either HA-E, E-
FLAG, M or S. As expected, N was readily detected
when co-expressed with HA-E or with M, but barely de-
tectable in culture medium when expressed alone or co-
expressed with S (Figure 2A, lanes 5 and 8) or E-FLAG
(which was also barely detectable in medium) (Figure 2B,
lane 3). These data support our hypothesis that SARS-
CoV N is capable of release into medium via association
with E, and suggests that FLAG tagged at the SARS-
CoV E carboxyl terminus significantly reduces E release
capacity in addition to impairing E incorporation into
VLPs.
To confirm that N release is associated with E in pelle-
table particle form, we subjected culture medium from
cells expressing E, E plus N, or E plus N and M to iodix-
anol density gradient fractionation, and found that E pri-
marily sedimented with co-expressed N at a slightly
lower density fraction compared to E expression alone
(Figure 2C). Particles formed by E or E plus N exhibited
an iodixanol density of 1.13 to 1.16 g/ml, whereas VLPs
formed by E, N and M displayed densities ranging from
1.11 to 1.13 g/ml. Combined, these data support the idea
that N released into medium is associated with E vesicles
when co-expressed with E.
RNA is not required for efficient E/N interaction
SARS-CoV N contains an RNA binding domain [30],
and results from our previous study indicate that RNA
can enhance the N-N interaction [22]. Here our goal
was to determine whether the presence of RNA is re-
quired for E/N interaction. HA-E or N was co-expressed
with GST tagged at the N amino terminus (GST-N). E
or N association with GST-N was assessed using a GST
pull-down assay in the presence or absence of RNase.
GST by itself was not capable of pulling down HA-E or
N (Figure 3A, lanes 5–6). RNase treatment significantly
reduced levels of co-pulled-down N (Figure 3A, lane 9),
which is consistent with past results [22]. However, the
same RNase condition did not reduce the amount of co-
pulled-down HA-E, suggesting that RNA is not required
for E/N interaction. We frequently observed slightincreases in pulled-down HA-E following treatment with
RNase (Figure 3A, lane 10 vs. lane 8). Since RNA binds
to N readily, it is likely that RNA-bound N molecules
may associate less efficiently with E.
E association domain is largely located in the N
carboxyl-terminal region
To map the N sequences involved in E association, we
constructed a set of GST-N fusions containing multiple
N coding sequences fused to the GST carboxyl terminus
(Figure 3B). Each GST fusion construct was transiently
co-expressed with E, and culture supernatants and cell
lysates were analyzed by Western immunoblotting. As
shown in Figure 3C, all GST fusions except for GST-N7
(containing N residues 2 to 86, lane 9) were released into
medium when co-expressed with E. None of the GST
fusions were readily detected in medium without co-
expressed E (data not shown), suggesting that the de-
tected GST-N fusions were released into medium via E
association, and that the E binding domains are largely
located in the N carboxyl-terminal region (likely involv-
ing amino acid residues 87 to 421). Results from a GST
pull-down assay (Figure 3D) provide further support for
this conclusion.
Cysteine residues are not required for E release, E/N
interaction, or E enhancement of VLP production
SARS-CoV and MHV E proteins are post-translationally
modified with palmitic acid. Lack of palmitoylation modi-
fication can markedly decrease SARS-CoV E membrane
association [16] and MHV E stability [17]. Substitution
mutations for cysteines-the palmitoylation targets in
MHV E can reduce virus yields, implying their importance
for MHV virus production [14,17]. Accordingly, we tried
to determine whether equivalent cysteines play a role in
SARS-CoV E/N interaction and VLP assembly by con-
structing an E mutant (designated EC3A) with alanine re-
placements for SARS-CoV E cysteine residues C40, C43
and C44. Supernatant and cell lysate samples containing
HA-E were analyzed under non-reducing conditions to
confirm the presence of disulfide bonds between SARS-
CoV E molecules. Results indicate the presence of an
18 kDa band (equivalent to an HA-E dimer) (Figure 4A,
lanes 2 and 11, arrowheads), which agrees with a previous
report [31]. As expected, only the E monomer was de-
tected in EC3A-containing samples under non-reducing
conditions (Figure 4A, lanes 3 and 12).
While most of intracellular E retains its monomeric form,
most released E was detected in dimeric form (Figure 4A,
lane 2 vs. lane 11), suggesting that released SARS-CoV E
proteins are largely linked by disulfide bonds. Interestingly,
EC3A was still efficiently released into medium and appar-
ently capable of promoting N release (Figure 4A, lanes 14
and 18). The relatively low level of medium HA-E observed
Figure 2 SARS-CoV VLP analysis. (A-B) 293 T cells were co-transfected with E tagged with either a FLAG or HA and N, M or S expression
vectors. Culture supernatants were collected 48 h post-transfection and subjected to Western immunoblotting. E proteins tagged with HA were
probed with an anti-HA antibody. The lane 4 band (panel B, arrowhead) resulted from the incomplete stripping of an anti-HA probe. (C) For
buoyant density gradient analysis, concentrated supernatants derived from E, E plus N, or E plus M and N transfection samples were centrifuged
through a 10-40% iodixanol gradient for 16 h. Equal quantities of ten fractions were collected from top to bottom. Fraction densities were
measured and SARS-CoV, E, M and N proteins analyzed by Western immunoblotting, using anti-HA, anti-M and anti-N antibodies as probes.
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lanes 17 vs. 8). Nevertheless, our data indicate that EC3A
produced VLPs as efficiently as wt when co-expressed with
both M and N (Figure 4B, lanes 10–12), suggesting that
SARS-CoV E cysteines are not involved in E release, E/Ninteractions, or VLP assembly. EC3A exhibited greater re-
lease efficiency compared to wt, implying that SARS-CoV E
cysteines are involved in the E trafficking process. However,
immunofluorescence results indicate that the EC3A subcel-
lular distribution pattern was similar to that of the wt.
Figure 3 Analysis of E/N association. (A) E/N association is RNA independent. 293 T cells were co-transfected with the designated constructs.
At 48 h post-transfection, equal amounts of the cell lysates were treated with or without 0.2 mg/ml DNase-free RNase A for 30 min at 25°C
followed by mixing with glutathione-agarose beads. Complexes bound to beads were pelleted, washed, and subjected to Western
immunoblotting. (B-D) Mapping of SARS-CoV N domains involved in E association. (B) Schematic representation of GST-N fusion constructs.
PCR-amplified fragments containing various portions of SARS-CoV N coding sequences were fused to the carboxyl terminus of GST, directed by a
mammalian elongation factor 1a promoter. (C) Association of GST-N fusion proteins with SARS-CoV E. 293 T cells were co-transfected with
SARS-CoV HA-E and indicated GST-N fusion construct. Cells and supernatants were collected at 48 h post-transfection, prepared, and subjected to
Western immunoblot analysis. (D) Co-precipitation of SARS-CoV E with GST-N fusion proteins. Equivalent amounts of cell lysates were analyzed by
GST pull down assays as described above.
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carboxyl-terminal tail significantly affects E release and
E/N interaction
E-FLAG was released at a lower efficiency level com-
pared to HA-E, suggesting that the carboxyl-terminal
tail domain may be involved in the E release process.
We hypothesized that the E-carboxyl tail is also involved
in E/N interaction. To test this idea, we constructed two
E mutants: EΔ76V (with the final carboxyl-terminal resi-
due valine removed) and E74LL/AA (with the carboxyl-
terminal dileucine motif 74-LL-75 replaced with
alanines). According to our results, (a) the E74LL/AA
mutant was capable of release, and (b) a positive correl-
ation exists between the release levels of co-expressed N
and E74LL/AA (Figure 5A, lanes 10–15). In addition,E74LL/AA was capable of producing VLPs as efficiently
as wt when co-expressed with M and N (Figure 5A,
lanes 16 vs. 17 and 18). These results suggest that 74-
LL-75 was not functionally involved in E release, E/N
interaction, or the promotion of VLP production. Con-
versely, EΔ76A was not capable of efficiently promoting
N release, and exhibited a reduced release capacity
(Figure 5B, lanes 12 to 15). GST pull-down assay data
suggest that the EΔ76V mutation markedly affected E/N
interaction, but exerted no major impacts on N/M asso-
ciation (Figure 5C, lanes 16 vs. 18). The level of GST-N-
associated E was significantly lower than that of GST-M-
associated E, suggesting that E/N association is not as
strong as E/M association (Figure 5C, lanes 15 vs. 17).
While pull-down assay results suggest an association
Figure 4 Changing all three cysteine residues to alanines exerted no negative effects on E release or its capability to interact with N or
VLP production. (A-B) 293 T cells were transfected with SARS-CoV HA-E expression vectors alone, or co-transfected with HA-E plus M and/or N
expression vectors. EC3A denotes alanine replacement of all three cysteine residues at E (C40, C43 and C44). Supernatants and cells were
collected at 48 h post-transfection and analyzed by Western immunoblotting. Aliquots of cell and supernatant samples containing E proteins
(panel A, lanes 1 to 3 and 10 to 12) were prepared without reducing reagent (β-mercaptoethanol). SARS-CoV E, M, and N were respectively
probed with anti-HA, anti-M and anti-N antibodies. Arrowheads indicate the position of HA-E dimer.
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cantly enhanced following M co-expression (Figure 5C,
lane 18 vs. Figure 5B, lanes 17 and 20). A possible ex-
planation is steric hindrance during VLP assembly. Note
that EΔ76V was still capable of promoting VLP produc-
tion as efficiently as the wt, despite defective packaging
into VLPs (Figure 5B, lane 20). This suggests that the
SARS-CoV E contribution to VLP production is inde-
pendent of its ability to be packaged into VLPs.
None of the mutations significantly affected SARS-CoV E
subcellular localization
To determine whether mutations affecting E subcellular
localization also partly accounted for altered release effi-
ciency, we co-expressed each mutant with a Golgi label-
ing marker (pECFP-Golgi). According to a confocal
microscopy analysis, wt and the EC3A, E74LL/AA, and
EΔ76V mutants largely localized in the Golgi area
(Figure 6A), suggesting that none of the mutations sig-
nificantly affected E subcellular localization. When
co-expressed with EGFP-tagged N, a fraction of N co-localized with EΔ76V in the perinuclear area; this stain-
ing pattern was barely distinguishable from that of cells
co-expressing HA-E and N-EGFP (Figure 6B). This im-
plies that even though EΔ76V may associate with N to a
certain extent, the association is insufficient for enabling
EΔ76V co-precipitation with GST-N (Figure 5C).
Discussion
To our knowledge, this is the first report of interaction
between SARS-CoV E and N proteins. Both SARS-CoV
spike (S) and E proteins can be released into medium;
however, unlike E, S cannot promote the release of co-
expressed N (Figure 2A). This suggests that N is incap-
able of associating with S, and supports the idea of spe-
cific E/N interaction. While RNA can enhance N/N
interaction, the presence of RNA is not necessary for E/
N interaction. Genetic analyses suggest that E binding
domains are largely located in the N carboxyl-terminal
region (Figure 3).
SARS-CoV M or E by itself can secrete into medium
as vesicles but not virus-like particles (VLPs) which can
Figure 5 Effects of E carboxyl tail mutations on E/N association and VLP production. (A-B) 293 T cells were transfected with HA-tagged E
expression vector alone or in combination with M and/or N expression vectors. 74LL/AA indicates alanine substitutions for two leucine residues
at the E carboxyl tail (74-LL-75). Δ76V denotes a deletion of the last carboxyl-terminal residue V76 from E. Supernatant and cells were harvested
at 48 h post-transfection, prepared, and subjected to Western immunoblotting. E or N proteins from medium or cell samples were quantified by
scanning the band densities from immunoblots. Ratios of HA-EΔ76V in media to those in cells were determined for each samples and normalized
to that of HA-E in parallel experiment. The level of N-associated VLP (M + N) production is determined as described in the legend to Figure 1. (C)
Removal of the last E carboxyl-terminal residue significantly affected E/N interaction. 293 T cells were co-transfected with HA-tagged wt or Δ76V
and GST, GST-M or GST-N expression vectors. GST-N and GST-M have GST tags at the amino-terminals of the SARS-CoV N and M coding
sequences, respectively. At 48 h post-transfection, cells and supernatants were collected and prepared for protein analysis. Aliquots of cell lysate
samples were subjected to GST pull down analyses (right-hand panel).
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N and E. It is likely that there may be a combination of
these different VLPs in culture medium when cells are
co-transfected with M plus E and N. The iodixanol
density gradient fractionation analyses suggest that re-
leased E vesicles and E-N VLPs exhibit slightly higherdensities compared to those of M-E-N VLPs (Figure 2C).
Since M is the major viral component, the strong pres-
ence of M molecules may exert a spatial effect that ex-
plains, at least in part, the lower density for M-E-N
particles. We consistently observed marked E-N VLP
yield enhancement following M co-expression. Since M
Figure 6 (See legend on next page.)
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Figure 6 Subcellular localization of SARS-CoV E and N proteins. (A) Subcellular localization of wt or mutant SARS-CoV E proteins. HeLa cells
were co-transfected with the indicated HA-tagged wt or mutant E expression vectors plus pGolgi-ECFP, which encodes a Golgi apparatus labeling
marker. (B) Co-localization of SARS-CoV E and N proteins. HeLa cells were co-transfected with SARS-CoV N bearing carboxyl-terminal tagged EGFP
(N-EGFP) and HA-tagged wt or Δ76V expression vectors. At 18 h post-transfection, cells were fixed and labeled with a primary anti-HA antibody
and a secondary rhodamine-conjugated anti-mouse antibody. Images represent the most prevalent phenotypes. Merged red/blue or red/green
fluorescent images are shown in right-hand column panels. Mock-transfected cells failed to yield any signal (data not shown).
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recruiting both E and N into VLPs, we do not consider
this a surprising result. In addition, M exhibits a notice-
ably higher N binding capacity than E (Figure 5C). VLPs
formed by M, E and N look more morphologically homo-
geneous than E-N VLPs, possibly due to additional inter-
molecular interactions between M/M, M/E and M/N.
SARS-CoV E is capable of undergoing oligomerization
triggered by both hydrophobic interaction and interchain
disulfide bond formation between cysteine residues
[16,31]. All three SARS-CoV E cysteine residues have
been shown to be post-translationally modified by palmi-
toylation [16]. Blocking MHV E palmitoylation results in
significantly impaired VLP assembly, suggesting that pal-
mitoylated E proteins are essential for murine corona-
virus assembly [14]. In the present study we found that
changing all three cysteines into alanines (EC3A) did not
exert negative effects on SARS-CoV E protein release or
VLP assembly (Figure 4). This suggests that E palmitoy-
lation or interchain disulfide bond formation is not re-
quired for SARS-CoV E protein release or VLP
assembly. Furthermore, we consistently detected higher
levels of EC3A compared to wt E in medium, suggesting
that EC3A is released more efficiently than wt E. One
possible explanation is that post-translational palmitoy-
lation or interchain disulfide bond formation restricts E
protein secretion.
Despite a higher release level compared to wt E, EC3A
did not produce higher VLP yields than wt E following
co-expression with M and N, suggesting no correlation
between SARS-CoV E release capacity and its contribu-
tion to efficient VLP production. Furthermore, EΔ76A
was still capable of enhancing VLP production even
though it was defective in both release and N associ-
ation. Although EΔ76A is capable of M association (as
shown by GST assays), it is not efficiently incorporated
into VLPs when co-expressed with M. A possible ex-
planation for this discrepancy is that the disruption of
cellular compartments allows E/M to associate at a
higher capacity, whereas less E/M association occurs in
assembly and budding compartments such as ER/Golgi,
resulting in smaller amounts of E being packaged into
virions. This scenario is compatible with the proposal
that E may promote virus assembly and/or budding by
facilitating membrane bending and scissions without
required packaging into virions. In support of thishypothesis, one research team has reported that E dele-
tion does not significantly affect SARS-CoV replication,
but that E-deleted mutants exhibit 100- to 1,000-fold
reductions in virus yields associated with decreased effi-
ciency during morphogenesis [32]. Although E/N inter-
actions may not be directly involved in virus assembly
and budding, it remains to be seen whether the SARS-
CoV E contribution to virus production requires effi-
cient E/M interaction.
Conclusions
Palmitoylation or interchain disulfide bond formation
appears to be dispensable for the SARS-CoV E enhance-
ment of VLP yields. The contribution of SARS-CoV E to
efficient VLP production is also independent of its re-
lease capacity, association with N, or VLP incorporation.
Additional experiments are required to clarify the bio-
logical relevance of SARS-CoV E/N interaction, and to
determine whether E/N interaction also exists in other
coronaviruses.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
CTW designed the experiments and wrote the paper. YTT, SMW and KJH
carried out the experiments and analyzed the data. All authors read and
approved the final manuscript.
Acknowledgements
The authors wish to thank Ming-Wei Guo for reagents and technical
assistance. This work was supported by Grants V98C1-021 and V99C1-013
from Taipei Veterans General Hospital, by Grant NSC 97-2320-B-010-002-MY3
and 100-2320-B-010-015-MY3 from the National Science Council, Taiwan, and
by a grant from the Ministry of Education, Aim for the Top University Plan.
Received: 15 January 2014 Accepted: 21 April 2014
Published: 27 April 2014
References
1. Lai MM: Molecular biology of coronavirus 1986. Adv Exp Med Biol 1987,
218:7–13.
2. Masters PS: The molecular biology of coronaviruses. Adv Virus Res 2006,
66:193–292.
3. Klumperman J, Locker JK, Meijer A, Horzinek MC, Geuze HJ, Rottier PJ:
Coronavirus M proteins accumulate in the Golgi complex beyond the
site of virion budding. J Virol 1994, 68(10):6523–6534.
4. Tooze J, Tooze S, Warren G: Replication of coronavirus MHV-A59 in
sac- cells: determination of the first site of budding of progeny virions.
Eur J Cell Biol 1984, 33:281–293.
5. Corse E, Machamer CE: Infectious bronchitis virus E protein is targeted to
the Golgi complex and directs release of virus-like particles. J Virol 2000,
74(9):4319–4326.
Tseng et al. Journal of Biomedical Science 2014, 21:34 Page 11 of 11
http://www.jbiomedsci.com/content/21/1/346. de Haan CA, Rottier PJ: Molecular interactions in the assembly of
coronaviruses. Adv Virus Res 2005, 64:165–230.
7. Hurst KR, Kuo L, Koetzner CA, Ye R, Hsue B, Masters PS: A major
determinant for membrane protein interaction localizes to the
carboxy-terminal domain of the mouse coronavirus nucleocapsid
protein. J Virol 2005, 79(21):13285–13297.
8. Kuo L, Masters PS: Genetic evidence for a structural interaction between
the carboxy termini of the membrane and nucleocapsid proteins of
mouse hepatitis virus. J Virol 2002, 76(10):4987–4999.
9. Narayanan K, Maeda A, Maeda J, Makino S: Characterization of the
coronavirus M protein and nucleocapsid interaction in infected cells.
J Virol 2000, 74(17):8127–8134.
10. Risco C, Anton IM, Enjuanes L, Carrascosa JL: The transmissible
gastroenteritis coronavirus contains a spherical core shell consisting of
M and N proteins. J Virol 1996, 70(7):4773–4777.
11. Sturman LS, Holmes KV, Behnke J: Isolation of coronavirus envelope
glycoproteins and interaction with the viral nucleocapsid. J Virol 1980,
33(1):449–462.
12. Wilson L, Gage P, Ewart G: Hexamethylene amiloride blocks E protein ion
channels and inhibits coronavirus replication. Virology 2006,
353(2):294–306.
13. Wilson L, McKinlay C, Gage P, Ewart G: SARS coronavirus E protein forms
cation-selective ion channels. Virology 2004, 330(1):322–331.
14. Boscarino JA, Logan HL, Lacny JJ, Gallagher TM: Envelope protein
palmitoylations are crucial for murine coronavirus assembly. J Virol 2008,
82(6):2989–2999.
15. Corse E, Machamer CE: The cytoplasmic tail of infectious bronchitis virus
E protein directs Golgi targeting. J Virol 2002, 76(3):1273–1284.
16. Liao Y, Yuan Q, Torres J, Tam JP, Liu DX: Biochemical and functional
characterization of the membrane association and membrane
permeabilizing activity of the severe acute respiratory syndrome
coronavirus envelope protein. Virology 2006, 349(2):264–275.
17. Lopez LA, Riffle AJ, Pike SL, Gardner D, Hogue BG: Importance of
conserved cysteine residues in the coronavirus envelope protein.
J Virol 2008, 82:3000–3010.
18. Vennema H, Godeke GJ, Rossen JW, Voorhout WF, Horzinek MC, Opstelten
DJ, Rottier PJ: Nucleocapsid-independent assembly of coronavirus-like
particles by co-expression of viral envelope protein genes. Embo J 1996,
15(8):2020–2028.
19. Baudoux P, Carrat C, Besnardeau L, Charley B, Laude H: Coronavirus
pseudoparticles formed with recombinant M and E proteins induce
alpha interferon synthesis by leukocytes. J Virol 1998, 72(11):8636–8643.
20. Hsieh PK, Chang SC, Huang CC, Lee TT, Hsiao CW, Kou YH, Chen IY, Chang
CK, Huang TH, Chang MF: Assembly of severe acute respiratory syndrome
coronavirus RNA packaging signal into virus-like particles is nucleocapsid
dependent. J Virol 2005, 79(22):13848–13855.
21. Huang Y, Yang ZY, Kong WP, Nabel GJ: Generation of synthetic severe
acute respiratory syndrome coronavirus pseudoparticles: implications for
assembly and vaccine production. J Virol 2004, 78(22):12557–12565.
22. Tseng Y-T, Wang S-M, Huang K-J, Lee AIR, Chiang C-C, Wang C-T:
Self-assembly of severe acute respiratory syndrome coronavirus
membrane protein. J Biol Chem 2010, 285(17):12862–12872.
23. Siu YL, Teoh KT, Lo J, Chan CM, Kien F, Escriou N, Tsao SW, Nicholls JM,
Altmeyer R, Peiris JSM, Bruzzone R, Nal B: The M, E, and N structural
proteins of the severe acute respiratory syndrome coronavirus are
required for efficient assembly, trafficking, and release of virus-like
particles. J Virol 2008, 82(22):11318–11330.
24. Maeda J, Maeda A, Makino S: Release of coronavirus E protein in
membrane vesicles from virus-infected cells and E protein-expressing
cells. Virology 1999, 263(2):265–272.
25. Sambrook J, Russell DW: Molecular cloning: a laboratory manual, ed 3rd Cold
Spring Harbor. N.Y.: Cold Spring Harbor Laboratory Press; 2001.
26. Cortes P, Weis-Garcia F, Misulovin Z, Nussenzweig A, Lai J-S, Li G,
Nussenzweig M, Baltimore D: In vitro V(D)J recombination: signal joint
formation. Proc Natl Acad Sci USA 1996, 93(24):14008–14013.
27. Wang S-M, Wang C-T: APOBEC3G cytidine deaminase association with
coronavirus nucleocapsid protein. Virology 2009, 388(1):112–120.
28. Shih Y-P, Chen C-Y, Liu S-J, Chen K-H, Lee Y-M, Chao Y-C, Chen Y-MA:
Identifying epitopes responsible for neutralizing antibody and DC-SIGN
binding on the spike glycoprotein of the severe acute respiratory
syndrome coronavirus. J Virol 2006, 80(21):10315–10324.29. Wang S-M, Chang Y-F, Chen Y-M, Wang C-T: Severe acute respiratory
syndrome coronavirus nucleocapsid protein confers ability to efficiently
produce virus-like particles when substituted for the human
immunodeficiency virus nucleocapsid domain. J Biomed Sci 2008,
15(6):719–729.
30. Huang Q, Yu L, Petros AM, Gunasekera A, Liu Z, Xu N, Hajduk P, Mack J,
Fesik SW, Olejniczak ET: Structure of the N-terminal RNA-binding domain
of the SARS CoV nucleocapsid protein. Biochemistry 2004,
43(20):6059–6063.
31. Liao Y, Lescar J, Tam JP, Liu DX: Expression of SARS-coronavirus envelope
protein in Escherichia coli cells alters membrane permeability.
Biochem Biophys Res Commun 2004, 325(1):374–380.
32. DeDiego ML, Álvarez E, Almazán F, Rejas MT, Lamirande E, Roberts A, Shieh
W-J, Zaki SR, Subbarao K, Enjuanes L: A severe acute respiratory syndrome
coronavirus that lacks the E gene is attenuated in vitro and in vivo.
J Virol 2007, 81(4):1701–1713.
doi:10.1186/1423-0127-21-34
Cite this article as: Tseng et al.: SARS-CoV envelope protein palmitoylation
or nucleocapid association is not required for promoting virus-like particle
production. Journal of Biomedical Science 2014 21:34.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
